Eikon Therapeutics vs Recursion (2026)
Two companies that built instruments rather than borrowing datasets, and they measure different things. Eikon watches proteins move inside living cells with super resolution microscopy descended from Nobel recognised imaging work, which produces dynamic measurement nobody else in this category has, and it has disclosed clinical work at the asset level. Recursion runs high throughput cellular experimentation at industrial scale, learning from images and multiomic data it generates itself, with disclosed partnership economics as a listed company and wet laboratory testing inside the loop. Both are strong platform arguments. Both also describe the optics and the assay beautifully while saying almost nothing about the models, which is the question a partner should press before signing anything.
- The differentiating asset is an instrument, applying super resolution live cell microscopy to watch individual proteins move rather than measuring a static endpoint.
- Regulatory activity is real at the asset level with disclosed clinical work, and public reporting documents the capital position.
- The platform feeds medicinal chemistry decisions rather than claiming to replace them, which is an honest account of what it does.
- High throughput cellular experimentation feeding machine learning on imaging and multiomic data at industrial scale, so the platform generates its own training data.
- Partnership economics are disclosed as a listed registrant, so the market's valuation of the platform is visible rather than described.
- Model hypotheses are tested in the wet laboratory before they advance, which puts empirical checking inside the loop.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eikon Therapeutics and Recursion are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eikon Therapeutics | Recursion |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | Not recorded |
| Headquarters | South San Francisco, CA | Salt Lake City, UT |
| Website | eikontx.com | recursion.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Eikon Therapeutics on any axis it scores. Set against Recursion, Eikon Therapeutics grades higher on AI Safety and PHI Stewardship and HIPAA and BAA Posture. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Recursion its top capability grade on AI Centrality and Commercial Transparency. Set against Eikon Therapeutics, Recursion grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Eikon Therapeutics or Recursion?
On the axes where the AI Health Index separates them, Eikon Therapeutics grades higher on AI Safety and PHI Stewardship and HIPAA and BAA Posture, and Recursion grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Recursion leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Eikon Therapeutics and Recursion differ most?
The widest separation the AI Health Index records between Eikon Therapeutics and Recursion is on AI Safety and PHI Stewardship, where Eikon Therapeutics grades B and Recursion grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Eikon Therapeutics and Recursion grade the same?
The AI Health Index grades Eikon Therapeutics and Recursion the same on several axes, including Autonomy and Oversight Model, FDA and Regulatory Status and AI Liability and Recourse. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Eikon Therapeutics and Recursion not disclosed?
At the last review, at least one of Eikon Therapeutics and Recursion published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both describe their measurement approach clearly and their computational layer barely at all, which is the shared gap in instrument led discovery and the question to put to either: what do the models actually do with the imaging data. Neither publishes cell line or donor provenance, which is where the bias question lives for platforms learning from their own biology. Recursion narrowed its internal pipeline in 2025, so any breadth claim predating that should be checked against the current programme list. Neither holds a located security attestation.